Technical Analysis for ZYME - Zymeworks Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 9.09 | -0.33% | -0.03 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | -0.33% | |
| Pocket Pivot | Bullish Swing Setup | -0.33% | |
| Outside Day | Range Expansion | -0.33% | |
| Overbought Stochastic | Strength | -0.33% | |
| Stochastic Reached Overbought | Strength | 0.33% | |
| Overbought Stochastic | Strength | 0.33% | |
| 20 DMA Support | Bullish | -1.20% | |
| 200 DMA Support | Bullish | -1.20% | |
| Pocket Pivot | Bullish Swing Setup | -1.20% | |
| Earnings Movers | Other | -1.20% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 1 hour ago |
| Up 2% | about 4 hours ago |
| Up 1% | about 5 hours ago |
| 60 Minute Opening Range Breakout | about 5 hours ago |
| Down 2 % | about 6 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Zymeworks Inc. Description
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Cancer Immunotherapy Monoclonal Antibodies Antibody Toxins Glycoproteins Her2 Protein Engineering Biological Systems Bispecific Monoclonal Antibody
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.14 |
| 52 Week Low | 6.015 |
| Average Volume | 454,965 |
| 200-Day Moving Average | 8.87 |
| 50-Day Moving Average | 10.03 |
| 20-Day Moving Average | 8.82 |
| 10-Day Moving Average | 8.70 |
| Average True Range | 0.44 |
| RSI (14) | 48.98 |
| ADX | 32.55 |
| +DI | 17.12 |
| -DI | 19.97 |
| Chandelier Exit (Long, 3 ATRs) | 8.57 |
| Chandelier Exit (Short, 3 ATRs) | 9.28 |
| Upper Bollinger Bands | 9.49 |
| Lower Bollinger Band | 8.15 |
| Percent B (%b) | 0.73 |
| BandWidth | 15.23 |
| MACD Line | -0.26 |
| MACD Signal Line | -0.41 |
| MACD Histogram | 0.146 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.02 | ||||
| Resistance 3 (R3) | 10.02 | 9.73 | 9.87 | ||
| Resistance 2 (R2) | 9.73 | 9.50 | 9.73 | 9.82 | |
| Resistance 1 (R1) | 9.42 | 9.36 | 9.58 | 9.42 | 9.77 |
| Pivot Point | 9.13 | 9.13 | 9.20 | 9.13 | 9.13 |
| Support 1 (S1) | 8.82 | 8.90 | 8.98 | 8.82 | 8.47 |
| Support 2 (S2) | 8.53 | 8.76 | 8.53 | 8.42 | |
| Support 3 (S3) | 8.22 | 8.53 | 8.37 | ||
| Support 4 (S4) | 8.22 |
